ANNUAL DIRECT MEDICAL COST OF MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES IN TURKIYE: A PUBLIC PAYER MICRO-COSTING ANALYSIS
Author(s)
Esra SAFAK YILMAZ1, Ceren Simsek, MSc2.
1Healthcare Policies Manager, Novo Nordisk, Ankara, Turkey, 2Istanbul University, Istanbul, Turkey.
1Healthcare Policies Manager, Novo Nordisk, Ankara, Turkey, 2Istanbul University, Istanbul, Turkey.
OBJECTIVES: Myocardial infarction (MI) is a major cardiovascular complication of type 2 diabetes and is associated with substantial healthcare resource use. This study aimed to estimate the annual per-patient direct medical cost burden attributable to MI among patients with type 2 diabetes in Türkiye and to identify the key cost drivers from the public payer perspective.
METHODS: A retrospective, micro-costing analysis was performed from the Turkish public payer perspective to estimate annual per-patient direct medical costs attributable to CKD among patients with type 2 diabetes. Average care pathways and resource use were captured across primary, secondary, and tertiary care settings. As no prospective national database routinely captures CKD-related resource utilization and costs, CKD-specific cost categories and resource items were defined using a structured approach, informed by estimates from 15 Turkish clinical experts. Unit costs were derived from the Healthcare Implementation Communiqué. Cost components included diagnostic tests, scheduled outpatient visits, planned inpatient care, pharmacological treatments, medical consumables and devices, monitoring tests, treatment-related adverse events, complications, and inpatient procedures. Total costs were calculated by assigning unit costs to resource use inputs and aggregating all components, with external review by a clinician advisory board.
RESULTS: The total annual per-patient direct medical cost of MI was estimated at TRY 40,297, corresponding to USD 867 using the current exchange rate. Pharmacological treatment was the largest cost component (TRY 19,354; 48.0%), followed by consumables and/or devices (TRY 13,458; 33.4%). Monitoring tests (TRY 2,375; 5.9%), diagnostic tests (TRY 2,029; 5.0%), and outpatient visits (TRY 1,983; 4.9%) contributed more moderately.
CONCLUSIONS: MI imposes a notable direct medical cost burden annually on the Turkish public healthcare system, with costs mainly driven by pharmacological treatment and consumable/device-related resource use.
METHODS: A retrospective, micro-costing analysis was performed from the Turkish public payer perspective to estimate annual per-patient direct medical costs attributable to CKD among patients with type 2 diabetes. Average care pathways and resource use were captured across primary, secondary, and tertiary care settings. As no prospective national database routinely captures CKD-related resource utilization and costs, CKD-specific cost categories and resource items were defined using a structured approach, informed by estimates from 15 Turkish clinical experts. Unit costs were derived from the Healthcare Implementation Communiqué. Cost components included diagnostic tests, scheduled outpatient visits, planned inpatient care, pharmacological treatments, medical consumables and devices, monitoring tests, treatment-related adverse events, complications, and inpatient procedures. Total costs were calculated by assigning unit costs to resource use inputs and aggregating all components, with external review by a clinician advisory board.
RESULTS: The total annual per-patient direct medical cost of MI was estimated at TRY 40,297, corresponding to USD 867 using the current exchange rate. Pharmacological treatment was the largest cost component (TRY 19,354; 48.0%), followed by consumables and/or devices (TRY 13,458; 33.4%). Monitoring tests (TRY 2,375; 5.9%), diagnostic tests (TRY 2,029; 5.0%), and outpatient visits (TRY 1,983; 4.9%) contributed more moderately.
CONCLUSIONS: MI imposes a notable direct medical cost burden annually on the Turkish public healthcare system, with costs mainly driven by pharmacological treatment and consumable/device-related resource use.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE464
Topic
Clinical Outcomes, Economic Evaluation, Health Policy & Regulatory
Topic Subcategory
Budget Impact Analysis, Cost/Cost of Illness/Resource Use Studies, Trial-Based Economic Evaluation
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory)